GlassScriptPhysician profile
Dariusz Chrostowski
NPI 1922100247
$13,244.38
in general payments reported to CMS, 2019-2025
29 companies · $2,659 in 2025
The $2,659 reported for 2025 was more than what 77% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,364 · 2020: $1,231 · 2021: $1,668 · 2022: $1,882 · 2023: $2,031 · 2024: $2,408 · 2025: $2,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,098.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,686.97 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,878.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,466.95 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $816.04 | 2020-2025 | Cuvitru, Hyqvia, Glassia |
| Pfizer INC. | $788.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $670.41 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $602.60 | 2019-2025 | Xembify |
| Csl Behring | $580.34 | 2019-2025 | Haegarda, Hizentra |
| Amgen INC. | $410.85 | 2021-2025 | Tezspire, Actimmune |
| Genentech USA, INC. | $296.78 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $295.08 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $292.73 | 2019-2025 | |
| Pharming Healthcare, INC. | $263.38 | 2022-2024 | Joenja, Ruconest |
| Optinose US, INC. | $229.69 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $209.31 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $137.53 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.63 | 2019-2023 | Spiriva Respimat |
| Shire North American Group INC | $92.99 | 2019 | |
| Jubilant Hollisterstier LLC | $89.80 | 2021 | |
| Bio Products Laboratory USA, INC. | $67.25 | 2020-2023 | Gammaplex, Coagadex |
| Kaleo, INC. | $66.04 | 2020-2024 | Auvi-Q |
| Lilly USA, LLC | $53.27 | 2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $40.52 | 2025 | Neffy |
| Horizon Therapeutics Plc | $38.63 | 2021-2023 | Actimmune |
| Merck Sharp & Dohme LLC | $36.46 | 2019-2023 | |
| Ionis Pharmaceuticals, INC. | $29.12 | 2025 | Dawnzera |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dariusz Chrostowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.